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Background: Febrile neutropenia (FN) is a common complication of cancer chemotherapy 
defined as fever with neutropenia below 1.0 x109 /L. Prompt antibiotic treatment is life-saving. 
Antipyretics (e.g. paracetamol) are commonly used during antibiotic treatment to reduce 
temperature and discomfort.   
A phase II randomised, placebo-controlled double-blinded trial of paracetamol during FN was 
completed at Wellington Hospital. This study aimed to determine whether paracetamol affects 
temperature or quality of life (QoL) during FN, and to assess biomarkers as potential secondary 
endpoints.  
Methods: Participants received 1g oral paracetamol or placebo six hourly for 42 h. Tympanic 
temperature was monitored four hourly. Blood was taken 0, 4, 24 and 72 h after FN 
presentation. In the current study cytokine bead array was used to determine levels of TNF-α, 
IL-6, IL-8 and IL-10, procalcitonin (PCT) was assessed by ELISA, and C-reactive protein (CRP) 
using an immunoturbidimetric method. Participants completed the EQ-5D-5L QoL 
questionnaire daily and the FACT-N questionnaire on day 3. 
Results: Of 37 enrolled patients, 22 participants developed FN and received at least one dose 
of paracetamol (n = 13) or placebo (n = 9). Treatment groups had comparable demographics 
and vital signs at baseline. Per pre-determined criteria, 23% and 33% of patients had successful 
treatment in the paracetamol and placebo groups respectively (not significant). 
Peak temperature was significantly lower in paracetamol- than placebo-treated patients on 
days 1 and 2 (difference 0.7°C and 0.6°C, respectively, p < 0.01 and p = 0.03), but not on day 3. 
Average daily temperature was also significantly lower in the paracetamol than placebo group.  
IL-6, IL-8, IL-10 and TNF-α were raised at baseline and/or 4 h and declined thereafter. PCT 
peaked at 24 h.  Presentation and 4 h levels of IL-6, IL-8, IL-10, PCT and TNF-α, as well as 24 h 
PCT and 72 h IL-8 levels, were associated with adverse outcome. IL-6 was higher in the placebo 
than paracetamol group at 24 h (p <0.02).  
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QoL scores were worse in the paracetamol group during the first two days of treatment 
(difference not significant).  
Conclusions: Paracetamol was an effective antipyretic during FN. Serum biomarkers change 
during FN, and IL-6 and IL-8 are promising secondary outcome measures for future trials. The 
adverse impact of paracetamol on QoL scores was unexpected and requires confirmation in a 
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Chapter 1 – Introduction 
1.1 An Overview of Febrile Neutropenia and Current Treatments 
Febrile neutropenia (FN) is a common complication of high dose chemotherapy (HDC) and is a 
medical emergency. 1 Of patients who develop malignancies, 16% die from a resulting 
complication of their treatment.2 It is important for FN to be promptly treated with broad 
spectrum antibiotics to avoid fatality; early intervention is lifesaving.3 FN is important because 
it can contribute to dose reductions or treatment delays, potentially compromising cancer 
treatment.4,5 Many studies describe variable definitions of FN, for example a review carried out 
in 2013 found 24 studies using different definitions of FN.6 The definition selected for the 
purpose of this study is consistent with the NCCN guidelines and has been prominently found 
in the literature. That is,  FN is defined by a fever (≥ 38.3°C on a single occasion or ≥38.0°C 
sustained over two h) and a low neutrophil count (< 1.0 x109/L in the blood).7 
Myelosuppression (bone marrow suppression) is the dose limiting toxicity of many cytotoxic 
chemotherapies.4,8 Chemotherapy can cause a reduced number of neutrophils and this 
absence of functional neutrophils may cause the immune system to be overwhelmed by 
rapidly developing infections.9,10 Patients undergoing HDC are particularly susceptible to 
develop FN, both the duration and severity of the neutropenia are established risk factors.9 
Other risk factors for development of FN include patient age, type of malignancy and a history 
of previous FN episodes.4,11 
FN is treated by administration of broad-spectrum antibiotics as soon as FN is diagnosed.3,4,8 
During antibiotic treatment, patients’ temperature and vital signs are typically monitored to 
determine FN resolution.  Although fever can be a useful marker of infection 12, it causes 
discomfort to patients, so various methods are often used to lower patient temperature.13 
These methods include paracetamol administration and physical measures such as tepid 
sponging and inducing hypothermia.  
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1.1.1 Temperature Modification Effects and Recent Research 
There is uncertainty about optimal methods and thresholds for temperature modification 
during FN.13 On one hand, as well as being indicative of infection,12 an elevated temperature 
may act to hinder the replication of the viral or bacterial agent causing the infection.14,15 On 
the other hand by supressing the high temperature, clinicians may inadvertently be 
suppressing an innate response to infection. In current NZ medical practice, it is common 
practice to try to reduce fever during FN, in an effort to provide comfort and relief.13,16  
No published randomised trial has studied temperature management to alleviate fever in 
patients presenting with FN.17,18  To determine the suitability of a phase III trial in FN patients, 
researchers at the Wellington Blood and Cancer Centre carried out a feasibility trial of 
paracetamol in FN. This was a phase II randomised, placebo-controlled trial. The aims of the 
trial were to determine whether paracetamol leads to a reduction in temperature during FN, 
to determine whether randomisation is acceptable to patients, and to investigate whether 
recruitment is sufficient for a potential phase III trial. 
1.2 Measuring outcomes in Febrile Neutropenia 
Infectious organisms cannot always be identified in FN and conventional haematological 
markers of infection may be absent in patients who have received high-dose chemotherapy; 
due to neutrophilia and leucocytosis as a side-effect of treatment. Therefore the resolution of 
FN is usually determined clinically.19 So studies investigating FN often use a combination of 
several measures to define ‘successful treatment’ rather than relying on temperature 
normalisation alone.20,21 For the purposes of the paracetamol trial, if fever were included in the 
primary outcome measure then the allocated intervention (paracetamol vs placebo) could 
interfere with the clinical outcome. Thus the trial was designed to overcome this, by stopping 
intervention treatment 12 h before the outcome period begins. It is desirable to have one or 
more secondary outcome measures that reflect the infection without being influenced by 
paracetamol.  
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1.3 Paracetamol and its Effect on Temperature, Serum Biomarkers 
and Quality of Life 
1.3.1 Paracetamol and its Effect on Temperature 
Paracetamol, or acetaminophen, is a drug commonly prescribed to relieve pain and reduce 
fever.18 It is readily accepted by patients and often self-prescribed as it is an ‘over the counter’ 
drug. It is metabolised by the liver and eventually excreted by through the kidneys.22 
Paracetamol is commonly administered to patients who present with fever with the intention 
of reducing temperature and pain. The effectiveness of this prescription in patients with FN as 
a complication of HDC has not yet been evaluated.  
The work of Paramba et al. compares the efficacy of different antipyretics (substances that 
reduce fever) in patients who presented with fever to the emergency department.23 The 
paracetamol was administered at presentation of fever, as in the current study, not as a 
prophylactic measure. Tepid sponging, intravenous and oral paracetamol were all deemed to 
significantly reduce temperature; however intravenous paracetamol was found to be the most 
effective method of rapid antipyresis, followed by oral paracetamol.23 Oral paracetamol is the 
most widely used antipyretic measure in FN in a survey of NZ haematologists and so is the 
method of administration for the current study.13 
Modifying the temperature of patients in an effort to reduce discomfort by administering 
paracetamol may have unexpected immunologic effects. For example, Prymula et al. 
investigated prophylactic paracetamol before childhood vaccination and whether it was able 
to reduce febrile complications (febrile seizures) in 459 healthy patients.24 Fever has been 
associated with vaccinations due to it instigating an antibody response, this is normally 
managed by anti-inflammatory cytokines so as not to harm the host. The percentage of 
patients who recorded a temperature above 38.0°C was 40-50% lower in the prophylactic 
paracetamol group.24 Also patients who received paracetamol reported significantly lower 
levels of pain if they went onto develop temperatures above 38.0°C than the group who did 
not receive paracetamol.24 This suggests that the paracetamol administration has limited the 
antibody response from the vaccination, decreasing its effectiveness. By contrast when 
paracetamol is administered in a therapeutic sense (not as a prophylactic measure) the 
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inflammatory signals will have already been initiated. So paracetamol should not reduce the 
serum biomarker levels if prescribed once the febrile episode has begun.24 This study serves as 
a good example of paracetamol and its effect on temperature in a febrile setting; but it does 
not delve into what the effect of paracetamol is in patients who are already unwell and to 
present with neutropenia. Consistent temperature measurement methods are required to be 
able to provide generalizable results in the FN setting.25 
Fever may be an important component of the physiological response to infection. The work of 
Mackowiak et al. indicated that at temperatures in the febrile range some bacterial strains die 
or are unable to replicate.26 So by administering antipyretics, clinicians may be inadvertently 
reducing the physiological mechanism of fighting infection.  
In conclusion, paracetamol is a widely used and safe antipyretic. The role which it has in FN has 
not yet been studied 18 and so the current study investigated its antipyretic effectiveness and 
potential other effects. 
1.3.2 Paracetamol and its Effect on Serum Biomarkers 
There is limited literature that has investigated whether paracetamol has an effect on serum 
biomarkers of infection. Pernerstorfer et al. randomised 30 healthy men to receive either oral 
paracetamol, aspirin or placebo, prior to intravenous endotoxin challenge (to induce fever).27 
The antipyretic that was most effective at reducing endotoxin-induced fever and heart rate 
was paracetamol. The authors noted that levels of serum TNF-α, IL-6 and IL-8 released in the 
paracetamol treated patients did not differ from the placebo-treated patients. The serum 
biomarkers rose to the same level, and had similar dynamics in both groups.27 This study 
suggests that paracetamol can reduce fever temperature, without affecting the levels of 
cytokines associated with the innate immune response. 
Biomarkers are defined as a ‘characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmalogical responses to 
therapeutic interventions.’28 Biomarkers of infection may be important as secondary outcome 
measures for this trial, because fever may be influenced by temperature modification. Blood 
cultures are only positive in 38% of people with FN, measuring bacteria is directly not useful.29 
Possible biomarkers of infection include cytokines which are released into the blood in 
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response to infection and as part of the inflammatory response. Some cytokines, conversely, 
act to limit this response so as to prevent harm to the host.   
Serum biomarkers associated with infection include C – reactive protein, procalcitonin and 
some interleukins.30 Some of these biomarkers could be used as prognostic or diagnostic 
biomarkers; indicating the, degree of infection, the resolution, or predicting the duration and 
severity of FN.31 Biomarkers which have often been studied and could provide the best 
potential to be a predictive marker are CRP, IL-6 and PCT and so these are the starting points 
for my investigation.1,31 
Serum biomarkers used in combination should provide more information than each one alone, 
and when looking for biomarkers more than one biological pathway should be considered 
because ‘multiple markers of the same phenomenon failed to provide additional 
information.’32 This is because each biomarker responds to infection by elevating and 
normalising slightly differently and at different times during the infection. A mixture of 
biomarkers may enable evaluation of FN status, the stage of FN and the prediction of FN 
complications and outcome. The work of Vanska et al. suggests the use of several predictive 
biomarkers in combination, due to the different times each biomarker peaks and presents a 
difference between patients who do and do not develop complications.33 If biomarker levels 
are only measured once in a patient then it may not provide a correct indication of patient 
infection. So if biomarker concentrations are measured several times during infection then 
may reveal its progression and provide more data to reduce the bias associated with individual 
variation.32 
It is plausible that the biomarkers of infection in severe FN are different from those in non-
neutropenic fever. This is because the absence of neutrophils and other myeloid cells 
(including eosinophils and monocytes) could influence biomarkers, the types of organisms may 
differ, and because chemotherapy-induced inflammation may confound findings. Therefore to 
be of most use to the current study I concentrated on papers which discussed biomarkers in a 
FN setting
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1.3.2.1 C - reactive protein 
C - reactive protein is the biomarker which is the current standard marker of infection and has 
been used to provide a prediction of outcome is CRP is an acute phase protein produced by the 
liver in response to monocyte secreted interleukin-6 in response to detection of foreign 
material in the body.34,35 CRP functions by recognising and binding to dying cells and bacteria 
to trigger the complement cascade and enhance phagocytosis of the invading material.34,36 This 
aims to clear the infection and limit detrimental effects to patients. Serum CRP concentration 
in healthy patients is < 10 mg/L, this rises rapidly during infection up to 20-fold.34 CRP is an 
obvious biomarker to investigate in the FN setting, as a test it is readily available in most 
hospital laboratories, and clinicians are familiar with its use and interpretation. Commonly CRP 
is analysed using an automated electrochemiluminescence immunoassay or cytokine bead 
array. 33  
One study by Vanska et al. found a significant difference in CRP levels at the time of 
presentation, between those who developed FN complications and those who did not. CRP 
was found to be > 100 mg/L in patients with FN due to bacterial or fungal infection.33,37 In an 
Emergency Department study, CRP was an independent risk factor for death or complications 
in FN.8 Juutilain et al found CRP to be the best predictor of sepsis, when compared to other 
biomarkers including PCT and fibrinogen.32 
Conversely, some recent literature has argued that CRP is not able to rapidly determine which 
patients presenting with FN are at high risk of complications.38-40 Further investigation of 
whether CRP can be used to predict FN prognosis is warranted. 
1.3.2.2 Procalcitonin 
Procalcitonin is released in response to stimulation by cytokines; it is produced in thyroid cells 
and also some cells of the liver and gut.41 PCT is the precursor to the hormone calcitonin33, 
which itself acts to reduce blood calcium levels. The half-life of PCT is 25-30 h and the normal 
range in healthy patients is < 0.5 ng/mL.41 This low value is due to PCT degradation during 
normal metabolism; conversely in cases of infection PCT levels can reach 500 ng/mL.31 
Methods used to measure its levels include an immune luminescence-based assay, automated 
electrochemiluminescence immunoassays and cytokine bead array.31,33 
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A number of studies have indicated that raised PCT is a poor prognostic factor in FN.40,42,43 
Patients with FN who developed complications had sustained PCT levels above 1.5 μg/L within 
the first 24 h, whereas PCT levels of those who did not develop complications remained ~ 0.1 
μg/L throughout the 3 day period.33 
A review and meta-analysis by Haeusler et al found that PCT levels peaked within the first 24 h, 
as early as 6 h after FN onset.6 The review found that at admission to hospital for FN, 
procalcitonin was markedly better than CRP at predicting serious adverse outcome.6 A recent 
study found that PCT could be used as a test for the presence of infection in patients 
presenting with FN, while also predicting a whether patients will have poor outcomes. This 
study defines elevated PCT levels as anything > 2.0 ng/mL.44   
In contrast, a review and meta-analysis of several papers concluded that PCT should not be 
used exclusively to predict severe infection in FN patients due to a high number of false 
positive.45 This may indicate that PCT is best used in conjunction with other clinical measures 
of biomarkers of infection. 
Overall, the literature suggests that PCT is a useful early indicator of FN complications, 
supporting its further investigation in this study. 
1.3.2.3 Interleukin-6 
The aforementioned interleukin - 6 is produced by monocytes, after they come in contact with 
foreign bacteria particles and therefore it is one of the earliest serum biomarkers to rise in 
response to infection.33,37 It is a pro-inflammatory cytokine as when it is produced its presence 
stimulates the production and differentiation of other interleukins to amplify the inflammatory 
response through T and B-cell activation.37 IL-6 stimulates the liver to produce acute phase 
proteins such as the previously mentioned CRP 33. Importantly, IL-6 itself is one of the body’s 
endogenous pyrogens 46 and its effect is blocked by certain antipyretics, so IL-6 may be 
particularly suitable as a biomarker for the paracetamol trial. IL-6 levels rapidly normalise after 
their initial increase, typically within a few days.33 IL-6 can be measured using an enzyme-
linked immune assay or cytokine bead array. 
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Because it rises early during an infection, IL-6 has potential value as a serum biomarker at the 
time of first presentation with FN. Several studies have investigated the utility of IL-6 to predict 
whether patients will develop bacteraemia.43  
Vanska et al. measured IL-6 levels in patients presenting with FN. At presentation, IL-6 levels of 
150-200 ng/L predicted a subsequent FN complication, compared to 50-100 ng/L in patients 
who did not develop complications; this difference was found to be statistically significant.33 
Therefore IL-6 may be used to exclude the possibility of high-risk infection.47 
Kwofie et al. investigated using a Bioplex suspension bead array system to assess IL-6 levels 
during FN as a predictor of subsequent complications. In this study of 48 adults who developed 
FN after high-dose chemotherapy, no statistically significant prognostic value of IL-6 levels was 
found.31 The authors noted that, as the half-live of IL-6 is short, the IL-6 levels of the 30% of 
patients involved in this study who were admitted from an outpatient setting may have 
already started decline by the time their blood sample was taken for this analysis.31 
Heney et al. found the serum concentration of IL- 6 to be < 12.5pg/mL in healthy patients.37 
1.3.2.4 Interleukin-10 
IL-10, like IL-6 is produced by monocytes , however it acts as an anti-inflammatory cytokine. IL-
10 inhibits the production of serum biomarkers which promote the inflammatory response.33 
This anti-inflammatory response ensures that the host is not damaged by and excessive 
immune response.48 IL-10 levels rise as soon as infection occurs, and then taper off in the first 
few days of infection.33 The concentration of IL-10 in 50 healthy volunteers was found to be < 
3.0pg/mL.49 IL-10 is measured using an enzyme-linked immune assay or a cytokine bead 
array.33 
In a study of FN in paediatric oncology patients, an association between early IL-10 levels and 
subsequent infections complications was sought.48 IL-10 levels in patients who had a positive 
blood culture were significantly higher than in those who had a fever of unknown origin.48 This 
study included 24 children and 36 episodes of FN – importantly, this means that some patients 
were included more than once, and may mean that a few patients’ IL-10 levels were 
overrepresented in the analysis.48 
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In a review in 2012 by Duell et al., the role of IL-10 in limiting innate immunity is discussed.50 
Duell et al. found the kinetics of IL-10 during infection may enable monitoring of the stage of 
infection. 
As well as assessing IL-6, Vanska et al. found that IL-10 levels at diagnosis of FN predicted 
which patients will go on to develop bacteraemia. However, the clinical utility of this 
information was not determined. Overall, this suggests that IL-10 could be used as a marker of 
bacteraemia at diagnosis, but whether it can predict complications, or be used to direct 
treatment has yet to be determined.  
1.3.2.5 Interleukin-8 and Tumour Necrosis Factor-α 
Tumour Necrosis Factor-α is a pro-inflammatory protein that is activated by macrophages as 
part of the acute phase response to infection.51 Phagocytes which recognise TNF-α are 
stimulated to produce Interleukin-8 (IL-8), which  is a cytokine that acts to promote the 
recruitment of neutrophils to the site of infection.52 The involvement of these two cytokines in 
inflammation means that they may be able to provide utilisable information for prediction of 
FN. Healthy concentrations of TNF-α and IL-8 were established as 11.2 ± 7.3 pg/mL and 12.9 ± 
13.9 pg/mL respectively by Arican et al.53 
IL-8 levels increase earlier than CRP levels during infection.47 Therefore it could represent an 
early predictor of infection or infection severity.  Few studies have investigated the predictive 
value of IL-8 in a FN setting. A recent study found that IL-8 and TNF-α levels could be used to 
exclude the possibility of high-risk FN.47 Miedema et al. found IL-8 to be an early indicator of 
whether or not paediatric patients had bacteraemia. They suggested that it may provide 
utilisable information if studied further in conjunction with other serum biomarkers.54 
Although research into measuring IL-8 and TNF-α levels is limited it would be reasonable to 
include it in our analysis in the hope of finding the best serum biomarkers for FN. 
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1.3.3 Paracetamol and its effect on Quality Of Life 
Treating the underlying cause of fever, in this case infection, is imperative for its resolution 23. 
Reducing a patient’s temperature may also importantly reduce the discomfort associated with 
fever.18 Quality of life is something which is increasingly considered in the treatment of 
patients with cancer. QoL is a multifactorial measure that can differ between individuals 
presenting with the same disease, clinical signs and biological measures; it is a subjective 
measure.55 Considering QoL ensures clinicians do not focus on the disease alone but also on 
the wellbeing of the patient.55 Cancer diagnosis causes stress, also the progression of the 
disease and resulting treatments can inhibit a patient’s ability to go about their normal tasks. 
Up to 75% of patients prefer to be treated in an outpatient setting, this improves QoL as they 
are able to continue more of their day to day activities.3 Furthermore patients may be less 
willing to complete treatment if it results in a reduction in their QoL. For example, elderly 
patients may wish to preserve QoL by abstaining from chemotherapy as it decreases their 
physical function ability and can lead to increased depression rates in the elderly.56  
As more has been discovered about the pathogenesis and mechanisms of cancer treatment 
which patients are given have improved in their ability to combat the disease.57  Improvements 
in treatment include greater effectiveness accompanied by decreased unwanted side effects of 
the treatment.55 So as treatments improve there is now a focus in modern cancer treatment to 
also maintain patients’ QoL as they undergo cancer therapy. 
QoL is commonly measured by the completion of a questionnaire; these questionnaires are 
designed to be easy to read and interpret and relevant to patients’ symptoms and situations. 
They assess patient symptoms, ability to function and their general wellbeing and mood.55 In 
patients with neutropenia, a QoL questionnaire enables health professionals to monitor their 
developing infection and investigate how the clinical signs are affecting the patient. In patients 
receiving chemotherapy a QoL questionnaire could be useful to give an indication of which 
patients will develop FN.55 
Patient quality of life is an important outcome of cancer therapy. If paracetamol 
administration is found to have no effect on FN outcomes, but improves QoL, then this would 
be evidence to warrant its use. As part of the febrile neutropenia trial, FACT-N and the shorter 
EQ-5D-5L questionnaire were assessed. 




It is well established that febrile neutropenia is a medical emergency requiring prompt and 
effective treatment. FN affects many patients undergoing HDC, and potentially results in 
death, or treatment delays. Thus there is a need to determine biomarkers which will reliably 
predict complications and indicate resolution or progression of FN. 
Currently,  it is not clear from literature what is the best method for managing temperature in 
FN. This study aims to investigate whether the accepted method of antipyresis (paracetamol) 
is indeed effective in patients with FN. Consistent temperature measurement is required to be 
able to provide generalizable results in the FN setting.25 Using data from the phase II trial, this 
study may indicate whether paracetamol has any immunologic effects, altering biomarker 
levels. 
Some of the studies analysed in this review involve only a small number of patients and 
therefore a small number of resulting episodes of FN. So it can be difficult to determine 
whether the serum markers of interest do in fact have discriminatory ability.  
CRP and procalcitonin are established serum biomarkers for FN and are frequently used in a 
clinical setting. IL-6, IL-10, IL-8, TNF-α are cytokines which were found to have prognostic 
impact in FN in some studies, or warranted further investigation. Interleukins and TNF-α are 
less routinely measures so may provide clinical feasibility issues, and they are less stable in 
patient circulation so their assessment is time-dependent.  
This study investigated the effect of paracetamol on temperature, serum biomarkers and 
quality of life during febrile neutropenia, using samples and data from the first randomised 
trial of temperature control strategies during FN. This project may enable the identification of 
serum biomarkers as possible secondary endpoints. Biomarkers to be measured are CRP, 
Procalcitonin, IL-6, IL-8, IL-10 and TNF-α. 
 
 
  Emily Bowden 
21 
 
1.4.1 Study Hypotheses 
The specific hypotheses for this study are: 
 That paracetamol decreases temperature during febrile neutropenia 
 That paracetamol delays resolution of serum markers of inflammation during febrile 
neutropenia 
 That paracetamol improves quality of life measures during febrile neutropenia 
1.4.2 Specific objectives of this project 
1.4.2.1 Paracetamol effects on temperature 
To assess the effect of paracetamol on temperature the following aims were achieved: 
 Calculate mean daily peak temperature and mean average daily temperature from 
case report forms for study participants 
 Statistically compare mean daily peak temperatures in patients allocated to 
paracetamol or placebo 
1.4.2.2 Serum markers of inflammation during febrile neutropenia 
To assess the serum biomarkers during FN the following aims were achieved: 
 Conduct a literature review of serum biomarkers of inflammation, which correlate with 
FN prognosis and/or are known to be affected by paracetamol use. 
 Analyse selected biomarkers using cytokine bead array or ELISA 
 Statistically analyse findings; stratify patients by treatment allocation or study 
outcomes 
1.4.2.3 Quality of Life measures 
To assess the effect of paracetamol on patient QoL the following aims were achieved: 
 Determine Quality of Life score from case report forms 
 Statistically analyse Quality of life score based on allocation to treatment 
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Chapter 2 – Materials and Methods 
2.1 Patient recruitment 
This study makes use of patient data and samples obtained within an existing phase II double-
blind, block randomised placebo-controlled trial of paracetamol during FN. Adult patients 
receiving chemotherapies carrying a high risk of FN (> 30%) were recruited from the 
Wellington Blood and Cancer Centre. The intended sample size was 50 patients, of which 14 
would enter treatment in both arms of the trial. This sample size was calculated to have an 
80% power (alpha 5%) to identify a 1.2°C difference in temperature between placebo- and 
paracetamol-treated patients. Inclusion criteria included age > 18 years and weight > 50 kg. 
Exclusion criteria include abnormal liver function, current regular use of paracetamol or 
contraindicating paracetamol use. Consenting patients who meet all study criteria are given 
serially numbered study packs containing either paracetamol treatment (1 g paracetamol 
every 6 h over 42 h) or placebo treatment. After starting antibiotic treatment, patients 
commenced paracetamol/placebo treatment if they presented with FN following their 
chemotherapy and meet defined criteria.  
The Multinational Association of Supportive Care in Cancer (MASCC) Risk Index score was used 
to determine which patients are at a low risk of FN complications. It is calculated by weighting 
the following risk factors; burden of FN with no or mild symptoms (weight = 5), with moderate 
symptoms (weight = 3) or severe symptoms or moribund (weight = 0); no hypotension (systolic 
blood pressure > 90 mm Hg, weight = 5); no chronic obstructive pulmonary disease (weight = 
4); solid tumour or no haematological malignancy with no previous fungal infection (weight = 
4); no dehydration requiring parenteral fluids (weight = 3); admitted as an outpatient (weight = 
3); and less than 60 years old (weight = 2). These scores are summated and patients assigned 
either a high-risk (score < 21) or low-risk (score > 21) status. Determining patient score was 
carried out retrospectively, blinded to treatment with a haematologist to ensure proper 
interpretation of clinical data. 
2.1.1 Successful treatment 
Successful treatment was defined at 72h from the initiation of study therapy by several 
factors; survival with no fever >38°C in the preceding 12 h, no change of initial antimicrobial 
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therapy, no serious medical event (defined as hypotension with systolic BP <90mm Hg for >1 h, 
respiratory failure requiring invasive or non-invasive ventilation, or intensive care transfer) in 
the preceding 72 h, and no recurrence of fever seven days after cessation of first-line 
antibiotics. 
2.1.2 Liver function 
Grading for transaminitis and hyperbilirubinemia determined from guidelines presented in 
appendix i. 
2.2 Paracetamol effects on temperature 
Patient temperature (°C) was measured using an infrared tympanic thermometer (Genius 2, 
Coridien, MA USA) every four hours for 72 h after presentation with febrile neutropenia. 
Values are recorded in written study case report forms (CRFs) and transferred to study 
database.  
2.3 Serum markers of inflammation during febrile neutropenia 
Blood samples were taken at 0, 4, 24 and 72 h after presentation with febrile neutropenia. 
Serum samples are stored at -80°C in spun Serum Separating Tubes (SST) gel tubes 
(Vacutainer®, BD, NJ, USA). 
2.4 Quality of Life measures 
Participants were presented in person with two kinds of QoL questionnaires to carry out in 
person; the Functional Assessment of Cancer Therapy questionnaire for patients with 
neutropenia (FACT-Ni) and the EQ-5D-5L questionnaire.  
Patients completed the EQ-5D-5L to assess QoL at 24, 48 and 72 h after beginning to receive 
either placebo or paracetamol. This questionnaire is a short standardised measure of health 
which patients can complete quickly. One portion of this questionnaire is a visual analogue 
scale (VAS) where patients indicate their health on a scale of zero to 100; where 100 is the best 
health they could imagine and zero the worst. The rest of this questionnaire is made up of five 
descriptive scales pertaining to mobility, ability to self-care, ability to carry out normal 
activities, pain and discomfort levels and anxiety and depression. Within each scale responses 
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are given through five levels of severity; no problems, slight problems, moderate problems, 
severe problems, extreme problems. The New Zealand version was used, with permission from 
EuroQol for the purpose of this study. 
Between 72 and 90 h the more extensive FACT-N neutropenia-specific questionnaire was 
completed. This questionnaire consists of 27 questions which were distributed into four 
subsections of well-being; physical, social/family, emotional and functional. Also there is a 
neutropenia-specific section which includes 19 questions which can be summarised into 
questions relating to worry, discomfort or flu symptoms. FACT-N scoring guidelines are were 
followed. 
Values from both questionnaires were recorded in written study CRFs and transferred to the 
study database.  
2.5 Laboratory Methods - Serum markers of inflammation during 
febrile neutropenia 
Cryopreserved blood samples thawed at the Malaghan Institute of Medical Research for two 
types of analysis:  
2.5.1 Bio-Plex Pro™ Human Cytokine 8-plex Assay 
Bio-Plex Pro™ Human Cytokine 8-plex Assay (Bio-Rad Laboratories Inc., CA, USA) measures: IL-
6, IL-8, IL-10, IL-2, IL-4, IFN-γ, TNF-α and GM-CSF. Of which IL-6, IL-8, IL-10, TNF-α had been 
identified to be of interest to this study. Samples prepared and run according to 
manufacturer’s instructions as follows:  
An aliquot of serum was taken off the top of blood samples and diluted 1:4 (40μL:160μL) in 
room temperature in the manufacturers sample diluent. A Bio-Plex Pro™ Wash Station (Bio-
Rad Laboratories Inc., CA, USA) was primed for the use of the flat bottomed filter plate. 
Standard solution reconstituted and incubated on ice for 30 minutes, then serially diluted four-
fold. Bio-plex coupled beads were vortexed for 30 s, and diluted in Bio-plex assay buffer (287.5 
μL beads: 5,463 μL assay buffer) and then protected from light. 50 μL of bead solution was 
added to each well of the assay plate, and wells were washed two times with 100μL of Bio-plex 
wash buffer using the Wash Station. Then 50μL of each sample, prepared standard and blank 
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solution were added to the plate in duplicate. Samples were sealed and protected from light 
with aluminium foil and shaken for 30 minutes at room temperature. Plates were then washed 
again three times with 100μL of Bio-plex wash buffer using the Wash Station. 
The concentrated detection antibodies they were vortexed and diluted (300 μL) in the 
manufacturer’s diluent (2700 μL). Then 25μL of the diluted detection antibodies was added to 
each well. Again, samples were sealed and protected from light with aluminium foil and 
shaken for 30 minutes at room temperature. Plates were then washed again, three times with 
100 μL of Bio-plex wash buffer using the Bio-Plex Pro™ Wash Station. Streptavidin-PE (100x 
concentrate) was diluted (60 μL) in Assay Buffer (5940 μL) and 50μL added to each well. 
Samples were protected from light and shaken for 10 minutes. Wells were washed three times 
with 100 μL of Bio-plex wash buffer using the Bio-Plex Pro™ Wash Station. Beads suspended in 
125 μL assay buffer sealed and agitated for 30 s. Finally the sealing tape was removed and the 
plates read using the Bio-Plex 100 suspension array system (Bio-Rad Laboratories Inc., CA, 
USA). 
Samples for the Bio-Plex Pro™ Human Cytokine 8-plex Assay were plated in the same 
configuration as the samples presented in Figure 1 and concentrations were automatically 
calculated using the Bio-Plex 100 suspension array system. 
2.5.2 Procalcitonin Human ELISA Kit 
Procalcitonin was measured using a Procalcitonin Human ELISA Kit (Abcam, Cambridge, UK). 
Product protocol used as follows: 
Diluents A, and B diluted in distilled water and the 20X wash solution also diluted in distilled 
water to yield a 1X solution. Biotinylated Procalcitonin Detection Antibody briefly spun and 
100 μL of 1X Assay Diluent B added to prepare a detection antibody concentrate. This 
detection antibody concentrate was then diluted 80-fold with 1X Assay Diluent B. 700X HRP-
Streptavidin concentrate was diluted 700-fold with 1X Assay Diluent B (100μL in 8mL). A 
serially-diluted standard was prepared from a 55mg/mL stock standard, resulting in 
concentrations of; 20000, 6667, 2222, 740.7, 246.9, 82.30, and 27.43 ng/mL. Clinical patient 
samples were diluted 2 fold in Diluent A. 100 μL of each standard and sample was added into 
appropriate wells in duplicate according to Figure 1. Wells were covered and incubated over 
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night at 4°C with gentle shaking. Solution was discarded and wells washed 4 times with 300μL 
of 1X Wash Solution using a multi-channel pipette. The plate was inverted and blotted against 
clean paper towels to ensure complete removal of liquid, which is essential for good 
performance. 100 μL of 1X Biotinylated Procalcitonin Detection Antibody was then added to 
each well and incubated for 1 h at room temperature with gentle shaking. Again the solution 
was discarded and the wash repeated, after which 100 μL of 1X HRP-Streptavidin solution was 
added to each well. Plates incubated for 45 minutes at room temperature with gentle shaking. 
Solution discarded and wells washed again before adding100 μL of TMB One-Step Substrate 
Reagent. Plates incubated for 30 minutes at room temperature in the dark with gentle shaking; 
finally 50μL of Stop Solution was added to each well. Absorbance was read at 450 nm 
immediately using the Tecan Infinite M1000 Pro plate reader (Tecan, Männedorf, Switzerland). 
Data exported from the plate reader to Tecan I Control (Tecan, Männedorf, Switzerland). 
A standard curve was generated from absorbance readings (Figure 1). Cytokine concentrations 
were determined from the calculation of the standard curve and resulting equation of the line; 
(A) y = 0.0007x and R² = 0.9997, (B) y = 0.001x and R² = 0.9983. 
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Figure 1: 96-well plate following procalcitonin ELISA. 
 
Column one and two on both plates contain serially diluted standard solutions (‘Std’) for the 
construction of the standard curve along with a negative control well (‘Blank’). Wells 
containing samples labelled as follows: first two digits indicate sample number, and third digit 
indicates sample number i.e. 1 = presentation, 2 = 4 h, 3 =24 h, and 4 = 72 h sample. 
Corresponding standard curves presented. 
2.5.3 C - reactive protein 
CRP was measured by the Wellington Hospital laboratory using a Cobas c501 Latex 
Immunoturbidimetric method, which was then analysed on the Cobas analyser (Roche 
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2.6 Statistical Analysis 
P values < 0.05 were considered statistically significant. 
2.6.1 Paracetamol effects on temperature 
Data was imported from the paper CRFs into the study spreadsheet, and SPSS (SPSS Statistics 
for Windows, Version 22.0, IBM Corp. NY, USA) was used for statistical analysis. Daily peak and 
mean daily temperature was determined for each participant for each of the three 24 h 
periods. Peak temperatures and average daily temperatures of paracetamol- and placebo-
treated patients were compared using the Mann-Whitney test .58 Changes in temperature over 
time were analysed using Friedman test with Dunn’s post-tests.59  
2.6.2 Serum markers of inflammation during febrile neutropenia 
Procalcitonin values were exported to Microsoft Excel. A standard curve was produced using 
linear regression of logged values, from which sample concentrations were generated (ng/mL). 
PCT, CRP and cytokine bead array data generated for each biomarker of interest was analysed 
using SPSS. 
Data generated by the analysis of serum biomarker which was below the Limit of Detection 
(LOD) for the two detection machines poses issues for analysis. Concentrations reported at or 
below the LOD mean that the machine was not sensitive enough to determine whether these 
low concentrations are the same, at the LOD or zero. A population which had samples below 
and above the LOD is not normally distributed and so parametric testing is not appropriate for 
analysis. Imputation and regression models are methods which have been used to negate the 
effect data below the LOD has on analysis. But these methods are not appropriate for this 
study due to small study size and individual variation being such a large contributing factor to 
the varied biomarker concentrations.60 For the purposes of this study, non-parametric 
statistical tests were used throughout, and cytokine levels below the LOD were handled as a 
single value below the LOD (Procalcitonin: 30 pg/mL and TNF-α: 5.8 pg/mL). This is a 
conservative approach, which should avoid over-interpretation of values below the LOD, but 
might lead to some differences between groups being missed.  
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 Serum biomarker concentrations compared between paracetamol and placebo-treated 
patients using Mann-Whitney tests.58 Changes in serum biomarkers over time were analysed 
using paired analyses (Friedman test with Dunn’s post-tests).59  
2.6.3 Quality of Life measures 
Daily health scores indicated on the EQ-5D-5L questionnaire were compared for each patient 
using SPSS. Percentage change in health score from the time of presentation compared 
between each group using the Mann-Whitney test.58 Changes in QoL over time were analysed 
using Friedman test with Dunn’s post-tests.59 
2.7 Consent and ethical approval 
This trial has been approved by the Health and Disability Ethics Committee of New Zealand 
(reference 13/STH/55). The trial was funded by a Health Research Council grant (reference: 
13/699) and was prospectively registered with the Australia New Zealand Clinical Trials 
Registry (reference: ACTRN12613000601730). 
All patients gave written informed consent to participate in the trial. This trial was designed 
and carried out in accordance with the principles of the Declaration of Helsinki and in 
accordance with the University of Otago’s Responsible Practice in Research – Code of Conduct.  
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Chapter 3 – Results 
3.1 Study CONSORT Flow Diagram, Participant Baseline Measures and 
Successful Treatment 
3.1.1 Study CONSORT Flow Diagram 
Fifty-four patients were assessed for study eligibility between 8th October 2013 and 31 May 
2015, 37 of whom were recruited and enrolled into the trial. Reasons for exclusion were: not 
meeting inclusion criteria declining to participate, or poor comprehension skills, poor English 
and learning difficulties. A Consolidated Standards of Reporting Trials (CONSORT) diagram 
showing enrolment, treatment allocation and follow-up is presented in Figure 2. 
Of the 37 enrolled patients, 19 were allocated to the paracetamol arm and 18 to placebo. The 
trial design involved randomisation before febrile neutropenia onset: as a consequence, not all 
enrolled patients developed an episode of FN and were eligible to commence study treatment 
– the reasons for this are given in Figure 1. Thirteen participants allocated to the paracetamol 
arm and 9 in the placebo arm received at least one dose of study treatment. Four patients 
discontinued study treatment before 48 h in the paracetamol group: three were transferred to 
the Intensive Care Unit (ICU) or High Dependency Unit (HDU), while the other was made nil-by-
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3.1.2 Study Participant Baseline Measures  
Table 1 shows baseline characteristics of all patients who received at least one dose of 
allocated treatment, according to allocation to paracetamol or placebo. Patient age, gender 
and prior chemotherapy did not significantly differ between the two groups. All patients had 
severely low neutrophil counts, defined as < 0.5 x109/L.  
Table 1: Baseline characteristics of the study population 
  Treatment:   
Baseline Characteristics Paracetamol  Placebo P 
  (n = 13) (n = 9)   
Age 
   Median (Range), years 60 (22 - 70) 57 (21 - 70) 0.85¹ 
Gender 




Acute Leukaemia Induction 6 (46%) 2 (22%) 
 Autologous Stem Cell 
Transplant 5 (39%) 4 (44%) 
 Other 2 (15%) 3 (33%) 
 MASCC Score 
   Median (Range) 21 (15 - 24) 21 (18 - 24) 0.74¹ 
High Risk MASCC Score 31% 22% 0.52² 
Temperature  
   Median (Range), °C 38.1 (37.9 - 39.2) 38.3 (37.3 - 38.9) 0.79¹ 
Neutrophils 
   Median (Range), x10⁹/L 0.0 (0.0 - 0.4) 0.0 (0.0 - 0.1) 0.56¹ 
Heart Rate 
   Median (Range), min-1 101 (65 - 123) 103 (58 - 152) 0.90¹ 
Systolic Blood Pressure 
   Median (Range), mm Hg 110 ( 88 - 132) 120 (99 - 134) 0.29¹ 
¹ Mann Whitney U Test, ² Fisher's Exact Test, ³ Pearson's Chi Square Test, 
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3.1.3 Clinical outcomes and toxicity 
Clinical outcomes of FN are summarized in Table 2. Of the patients who started paracetamol or 
placebo treatment, six met criteria for successful treatment, as defined in the study protocol, 
three in each group. The reasons for treatment failure are; fever > 38.0°C between 60 and 72 
h, escalation of initial antibiotic regimen, hypotension (< 90 mm Hg) for longer than an hour, 
requiring ventilation, admission to the ICU or HDU, and finally recurrence or fever within 7 d of 
finishing antibiotic therapy. Note that some patients met more than one criterion for 
treatment failure.  
All patients from the paracetamol-treated group were alive 30 days after FN onset, whereas 2 
of the 9 placebo-treated patients had died within this time period (difference not significant). 
One placebo-treated patient died on day 7 after starting study treatment, due to neutropenic 
enterocolitis with Escherichia coli septicaemia, despite intensive care therapy. The other 
placebo-treated patient died on day  13 after starting study treatment, due to pneumonia (no 
causative organism proven), and was managed in a palliative manner. 
 Table 2: Study treatment success and failure  
  Treatment:   
 
Paracetamol  Placebo P 
  (n = 13) (n = 9)   
Successful treatment 3 (23%) 3 (33%) 0.48 1 
Treatment failure reasons:       
Fever ≥ 38.0°C between 60-72 hours 4 (31%) 4 (44%) 0.42 1 
Escalation of initial antibiotics 7 (54%) 6 (67%) 0.44 1 
Systolic BP < 90mm Hg for >1h OR 
ventilation OR ICU/HDU 
4 (31%) 3 (33%) 0.63 1 
Fever recurrence within 7d of stopping 
antibiotics 
3 (23%) 3 (33%) 0.48 1 
Length of hospital stay, median (range) days 13 (3 - 52) 9 (4 - 29) 0.43 2 
Alive at day 30 13 (100%) 7 (78%) 0.16 1 
1 Fisher's Exact Test; 2 Mann-Whitney U Test; ICU, intensive care unit; HDU, high 
dependency unit; BP, blood pressure 
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3.1.3.1 Liver Toxicity 
There was no significant difference between treatment groups in any of the liver function test 
concentrations at presentation, 24 h, or 72 h (Mann Whitney U Test) as shown in Table 3. One 
patient in the paracetamol-treated group had grade one transaminitis by 72 h. However upon 
consulting patient records it could be seen that this patient also presented with grade one 
transaminitis.  Another placebo-treated patient presented with grade one liver 
hyperbilirubinaemia, their bilirubin levels had returned to a normal level by 24 h. 
Table 3: Median liver function test levels at presentation, 24 h and 72 h.  
  Treatment:   
 
Paracetamol  Placebo P 
  (n = 13) (n = 9)   
Alanine Aminotransferase (reference range: 5 - 40 U/L) 
  Presentation, median (range) 13 (6 - 173) 9 (7 - 51) 0.43 
24 h, median (range) 15 (6 - 111) 11 (8 - 54) 0.96 
72 h, median (range) 13 (5 - 123) 14 (6 -103) 0.85 
Alkaline Phosphatase (reference range: 44 - 147 U/L) 
  
Presentation, median (range) 47 (40 - 85) 53 (43 - 119) 0.16 
24 h, median (range) 44 (26 - 72) 52 (45 - 183) 0.11 
72 h, median (range) 45 (20 - 87) 58 (23-336) 0.19 
Blood Bilirubin (reference range: 2 - 20 μmol/L) 
  
Presentation, median (range) 9 (5 - 47) 9 (4 - 13) 0.79 
24 h, median (range) 13 (4 - 28) 13 (6 - 27) 0.95 
72 h, median (range) 8 (3 - 15) 9 (3 - 24) 0.43 
3.2 Effect of Paracetamol on Temperature 
For the purpose of the trial, temperature was recorded every four hours for 72 h for all 
patients. However when study participants presented with high temperatures their 
temperature was measured more frequently. This is so that nursing and clinical staff could 
monitor fever and intervene if necessary to reduce patient temperature. For the purpose of 
this study to average all temperature recordings would result in bias in the patients who 
maintained high fevers throughout the study period. So the daily mean temperature is 
calculated from the temperature recordings which were closest to the 4 hour intervals. By 
contrast, daily peak temperature is calculated from the peak temperature recorded at any 
time during the 72 h period. 
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3.2.1 Effect of Paracetamol on Daily Peak Temperature in Paracetamol and 
Placebo Treated Groups 
Figure 3: Daily peak temperatures 
 
A: Line graph of mean peak daily temperatures for all patients over three days. 95% confidence 
intervals are shown at each time point. B: Parallel box plot depicting patient peak daily 
temperatures. Range (whiskers), inter-quartile range (box), and median (bold centre line) 
values are depicted for paracetamol- and placebo-controlled patients. Coloured circles 
represent outliers and coloured asterisks represent extreme outliers. Dotted horizontal line at 
37°C indicates normothermia. 
Figure 3 (A) shows a reduction in median peak temperature over the three day period. 
Wilcoxon signed-rank test determined that for both treatment groups there was a statistically 
significant decrease in peak temperature between days 1 and 2 (day 1 median = 38.6°C; day 2 
median = 27.9°C; median difference was -0.6°C; p = < 0.01). Eighteen patients showed a 
temperature reduction over this period (11 and 7 from the paracetamol and placebo groups, 
respectively). However, two patients in both groups showed a small increase in temperature 
during this period (< 0.7°C). 
Peak temperature by treatment allocation is shown in Figure 3 (B). Paracetamol led to 
significantly reduced peak temperature, compared to the placebo group on both Day 1 and 
Day 2. Mann Whitney tests were used to determine the median difference in peak 
temperature was 0.7°C (p < 0.01) on day 1 and on day 2 was 0.6°C (p = 0.03). The decline in 
* 
(A) (B) 
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mean peak temperature between Day 1 and Day 2 was statistically significant within each 
treatment group (paracetamol, p < 0.01; placebo, p < 0.01, Wilcoxon Matched Pairs). In 
contrast, no significant difference was found between groups by day 3. 
3.2.2 Effect of Paracetamol on Daily Mean Temperature in Paracetamol- and 
Placebo-Treated Groups  
Figure 4 A shows the mean average temperature throughout the monitored period. The mean 
temperature in both treatment groups is reduced from day 1 to day 2, but by day 3 there is an 
increase in the placebo treated group’s mean temperature, reducing the difference between 
the two treatment groups. Day 1 and Day 2 differences in average temperature between 
treatment groups were found to be significant (p = 0.03 and p = 0.03, respectively) when 
tested with Mann Whitney U-Test. The parallel box plot (Figure 4 B) shows a lower mean 
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A: Line graph of mean daily average temperatures for the all patients over three days. 95% 
confidence intervals are shown for each time point.  B:  Parallel box plot depicting average 
patient daily temperatures. Range (whiskers), inter-quartile range (box), and median (bold 
centre line) values are depicted for paracetamol- and placebo-controlled patients. Coloured 
circles represent outliers and coloured asterisks represent extreme outliers. Dotted horizontal 
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3.2.3 Effect of Paracetamol on Individual Temperatures measured 4-hourly in 
Paracetamol- and Placebo-Treated Groups 
 Mean temperature of the two populations are presented in Figure 5 with 95% confidence 
intervals indicating the range of temperatures across the 72 h period. Mean temperature of 
the two treatment groups was the same at the time of FN presentation. A difference in 
temperature between groups became apparent by 4 h. The distribution of temperature is 
significantly different across treatment groups at 4 h, 8 h, 24 h, 28 h, 36 h and 40 h (p = 0.02, p 
< 0.01, p = 0.03, p < 0.01, p = 0.01 and p = 0.03 respectively – Mann Whitney U Test) as 
indicated on the graph. From 40 h there was a reduction in the difference in mean 
temperatures between the two groups. 
Figure 5: Effect of paracetamol on temperature measured 4-hourly in treatment groups 
 
95% confidence intervals are shown at each time point for paracetamol- and placebo-
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3.3 Paracetamol and its Effect on Serum Biomarkers 
3.3.1 Baseline serum biomarkers 
Baseline samples from all participants were available for analysis. No significant differences 
between the treatment groups for any of the baseline concentration of biomarkers were found 
using Mann Whitney U Tests, as shown in Table 4. The range of concentrations for CRP, PCT, IL-
6, IL-8 and IL-10 are large among both treatment groups at this time. By contrast, the range of 
TNF-α concentration was much smaller than the other investigated biomarkers. All biomarkers 
were elevated from reported reference ranges. 
Table 4: Baseline biomarker concentrations compared between treatment groups 
  Treatment:   
Baseline Biomarkers Paracetamol  Placebo P 
  (n = 13) (n = 9)   
C-Reactive Protein       
Median (Range), mg/L 25 (8 - 192) 54 (31 - 133) 0.06 
Procalcitonin 
   Median (Range), pg/mL 30 (30 - 228) 30 (30 - 655) 0.95 
IL-6 
   Median (Range), pg/mL 38 (11 - 3969) 43 (22 - 5573) 0.70 
IL-8 
   Median (Range), pg/mL 45 (11 - 2595) 78 (22 - 1648) 0.74 
IL-10 
   Median (Range), pg/mL 8 (6 - 3141) 9 (6 - 752) 0.60 
TNF-α 
   Median (Range), pg/mL 13 (6 - 71) 14 (6 - 61) 0.65 
 
3.3.2 Serum Biomarker association with adverse outcomes 
To seek associations between serum biomarkers and adverse outcomes, patients were 
stratified by outcome of FN: Seven out of 22 patients had an adverse outcome of FN defined as 
a systolic blood pressure < 90 mg/Hg for over an hour, requiring ventilation or admission to the 
Intensive Care Unit or the High Dependency Unit, of which three were in the placebo-treated 
group and four in the paracetamol-treated group. Mann-Whitney U-Tests were carried out to 
determine whether serum biomarker levels at presentation correlated with adverse outcomes. 
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Table 5 indicates the levels of the selected biomarkers according to presence or absence of an 
adverse outcome. CRP levels did not correlate with adverse outcome. In contrast, presentation 
and 4 h concentrations of IL-6, IL-8, IL-10, TNF-α and PCT were significantly higher in those 
patients who were admitted to ICU or HDU, required ventilation, or developed hypotension. 
This elevation of was also seen the 72 h IL-8 samples of patients who developed an adverse 
outcome, when compared to those who did not develop such outcomes. 
Significant differences from Table 5 are presented below in a boxplot (Figure 6). Figure 6 
depicts the vast difference in biomarker concentration between patients who had adverse 
outcomes and those who did not. The range of serum concentrations are much lower and have 
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Table 5: The relationship between serum biomarkers and clinical outcome 
  
Admitted to ICU / HDU or systolic 
BP < 90 mm Hg P  
  Yes No 
C-Reactive Protein (mg/L, median) 
   
Presentation (range), n = 22 68 (14 - 192) 39 (8 - 94) 0.24 
72 Hours (range), n = 18 130 (70 - 197) 74 (8 - 266) 0.10 
IL-6 (pg/mL, median) 
   
Presentation (range), n= 22 902  (43 - 5,573) 30 (11 - 511) <0.01* 
4 Hours (range), n = 21 1491 (44 - 26,335) 45 (10 - 745) <0.01* 
24 Hours (range), n = 19 60 (15 - 4,164) 34 (5 - 125) 0.13 
72 Hours (range), n = 18 45 (8 - 841) 10 (4 - 616) 0.19 
IL-8 (pg/mL, median) 
   
Presentation (range), n= 22 429 (29 - 2,595) 40 (11 - 271) <0.01* 
4 Hours (range), n = 21 575  (37 - 29,263) 90 (17 - 363) <0.01* 
24 Hours (range), n = 19 113 (37 - 2,403) 38 (11 - 266) 0.09 
72 Hours (range), n = 18 120 (30 – 1,317) 27 (7 - 254) 0.02* 
IL-10 (pg/mL, median) 
   
Presentation (range), n= 22 120 (11 – 3,141) 7 (6 - 12) <0.01* 
4 Hours (range), n = 21 347 11 – 3,762) 8 (6 - 14) <0.01* 
24 Hours (range), n = 19 11 (7 - 319) 8 (4 - 12) 0.19 
72 Hours (range), n = 18 9 (5 - 121) 7 (6 - 11) 0.33 
TNF-α (pg/mL, median) 
   
Presentation (range), n= 21 27 (9 - 71) 13 (6 - 17) 0.02* 
4 Hours (range), n = 21 45 (11 - 159) 14 (6 - 19) <0.01* 
24 Hours (range), n = 19 16 (7 - 60) 12 (6 - 21) 0.26 
72 Hours (range), n = 18 12 (7 - 24) 11 (6 - 20) 0.72 
Procalcitonin (pg/mL, median) 
   
Presentation (range), n= 22 153 (30 - 655) 30 (30 - 38) <0.01* 
4 Hours (range), n = 22 331 (30 – 1,458) 30 (30 - 44) 0.01* 
24 Hours (range), n = 19 290 (30 – 1,448) 30 (30 - 465) 0.06 
72 Hours (range), n = 17 114 (30 – 1,717) 30 (30 - 109) 0.35 
Serum biomarker concentrations stratified by whether or not patients were admitted to 
ICU/HDU or presented with a systolic blood pressure < 90 mm Hg. Significance tested using 
Mann Whitney U-Tests. 
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Figure 6: Biomarker concentration stratified by development of adverse outcomes.  
 
Parallel box plot depicting range (whiskers), inter-quartile range (box), and median (bold centre line) biomarker concentrations are depicted for 
patients who were (red) or were not (grey) admitted to ICU/HDU, or developed hypotension (< 90 mm Hg) or required ventilation. Coloured circles 
represent outliers and coloured asterisks represent extreme outliers. Statistical significance indicated where p <0.05, only statistically significant results 
presented. 
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3.3.3 Serum biomarkers over time 
IL-6 and IL-8 exhibited similar dynamics throughout the first 72 h of FN, shown in Figure 7. 
Their concentrations significantly increased from presentation to peak in the 4 h samples (p < 
0.01 for both cytokines). From 4 h the concentrations of both IL-6 and IL-8 decreased to 24 h (p 
< 0.01 for both cytokines) and continued to decrease further to 72 h concentrations (p = 0.02 
and p = 0.01, respectively). 
Both IL-10 and TNF-α showed little variation throughout FN. Peak IL-10 (median 9.84pg/mL) at 
four hours was significantly higher that its presentation, 24 h or 72 h median concentration (p 
< 0.01, p < 0.01and p < 0.01, respectively). TNF-α concentration also peaked in the four hour 
samples (median 15.60pg/mL), which was significantly different to the other three time points 
(baseline p < 0.01, 24 h p < 0.01 and 72 h p = 0.02).  
Many of the PCT samples were equal to or below the limit of detection for the ELISA test 
(30pg/mL) hence the median line depicted in Figure 7 is constant. However, the 95% 
confidence intervals point to a possible trend in the change in concentration throughout FN. 
There is a significant increase in PCT from presentation to 24 h and from presentation to 72 h; 
p = 0.05 and p < 0.05, respectively.  
Due to sample availability and cost, only the presentation and 72 h samples of CRP were 
analysed. The 72 h CRP samples had a significantly higher median concentration than the 
presentation samples (p < 0.01, median difference was 28 pg/mL).  
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Figure 7: Median line graph for each biomarker among all patients during FN. 
Whiskers indicate 95% confidence intervals. Asterisks indicate significance (p < 0.05) 




IL-10 C-Reactive Protein 
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3.3.4 Paracetamol effects on Serum biomarkers  
To investigate whether allocation to paracetamol or placebo treatment was associated with a 
significant difference in serum biomarker levels, concentrations were compared for each 
biomarker at each time point as depicted in Figure 8. Mann Whitney – U test found a 
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Figure 8: Log concentration for each biomarker at each presentation, 4 h, 24 h and 72 h 
 
Paracetamol- (blue circles) and placebo-treated (green circles) patients at presentation, 4 h, 24 
h, and 72 h for; PCT, IL-8, TNF- α, IL-10, IL-6 and CRP. Dotted line indicates Limit of Detection 
(LOD) for each cytokine. 
* 
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3.4 Paracetamol and its Effect on Quality of Life 
Quality of life was measured during the first 72 hours of FN using two different questionnaires 
which patients completed. This was carried out to monitor whether the administration of 
paracetamol was having an effect on patient well-being. Four patients completed none of the 
QoL questionnaires. 
3.4.1 EQ-5D-5L Visual Analog Quality Score between paracetamol vs placebo 
patients 
A high EQ-5D-5L visual analogue score indicated a better self-reported quality of life (range 0-
100). There were no significant difference in median visual analogue quality scores between 
the placebo and paracetamol treated groups at 24, 48 or 72 h (p = 0.12, p = 0.07, p = 0.61, 
respectively) when tested with Mann Whitney U-Tests. Figure 9 shows that the median health 
score is lower at each time point in the paracetamol than placebo group. The difference in 
median health score between treatments is greatest at 24 h is reduced by 72 h. Figure 9 also 
highlights the wide range of responses which the study population gave to indicate their 
quality of life, which can be attributed not only to differing quality of life but to individual 
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Figure 9: Daily visual analogue health scores life by treatment allocation.  
 
Parallel box-plot depicting range (whiskers), inter-quartile range (box), and median (bold centre 
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3.4.2 EQ-5D-5L Visual Analog Score Quality of Life from 24 to 72 hours 
Figure 10 shows the median EQ-5D-5L Visual Analog QoL Score for the entire study cohort; the 
study population median increased from 24 h to 72 h. The median improvement (median 
difference = 5) was statistically significant in from 24 h to 48 h when tested using paired 
analyses (Wilcoxon signed-rank test: p < 0.01). 
Figure 10: Population median daily visual analogue health score from 24 to 72 h  
 
Whiskers indicate 95% confidence intervals. Number of patients at each time point depicted on 





n = 18 n = 16 n = 15 
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3.4.3 The EQ-5D-5L descriptive system as a health profile 
For each of the five dimensions (mobility, self-care, usual activity, pain/discomfort, and 
anxiety/depression) of the EQ-5D-5L questionnaire patients were asked indicate their level of 
problems associated with that aspect of their life; no problems, slight, moderate, severe, or 
extreme problems. Patient responses are summarised in Table 6 by paracetamol and placebo 
treatment for 24, 48 and 72 h. No patient from either treatment group reported severe or 
extreme problems in regards to their mobility, self-care, pain, or anxiety. However patients 
reported a range of problems with their ability to carry out their usual activities. This may be 
due to patients staying at the hospital during their FN.  Table 6 is further summarised in a 
series of graphs (Figure 11) depicting the proportion of patients who reported any degree of 
problem.  
A higher proportion of paracetamol treated patients reported problems with their ability to 
self-care or to carry out their usual activities, than the placebo group patients, as shown in 
Figure 11. The proportion of patients reporting pain/discomfort issues at 24 h and 48 h was 
reduced in both treatment groups’ by 72 hours. Less than 40% of patients in either treatment 
groups reported feeling any degree of depression or anxiousness at any point during the first 




  Emily Bowden 
53 
 
Table 6: Percentage of study population reporting problems by treatment 
    24 Hours  48 Hours  72 Hours  
  
Paracetamol Placebo Total Paracetamol Placebo Total Paracetamol Placebo Total 
EQ-5D Dimension n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Mobility 
No Problems 6 (67) 4 (50) 10 (59) 4 (44) 5 (71) 9 (56) 6 (75) 7 (88) 13 (81) 
Slight Problems 2 (22) 4 (50) 6 (35) 3 (33) 2 (29) 5 (31) 2 (25) 
 
2 (13) 
Moderate Problems 1 (11) 
 




1 (13) 1 (6) 
Severe Problems   
  
  
     Extreme Problems                   
Self-Care 
No Problems 8 (80) 7 (88) 15 (83) 6 (67) 7 (100) 13 (81) 5 (63) 8 (100) 13 (81) 
Slight Problems 1 (10) 1 (13) 2 (11) 3 (33) 
 
3 (19) 3 (38) 
 
3 (19) 
Moderate Problems 1 (10) 
 
1 (6)   
     Severe Problems   
  
  
     Extreme Problems   
  
  
     
Activity 
No Problems 2 (20) 2 (29) 4 (24) 1 (11) 3 (50) 4 (27) 1 (13) 4 (57) 5 (33) 
Slight Problems 3 (30) 1 (14) 4 (24) 3 (33) 1 (17) 4 (27) 3 (38) 1 (14) 4 (27) 




1 (14) 1 (7) 
Severe Problems   1 (14) 1 (6) 2 (22) 
 
2 (13) 2 (25) 
 
2 (13) 
Extreme Problems 2 (20) 2 (29) 4 (24)   2 (33) 2 (13) 2 (25) 1 (14) 3 (20) 
Pain 
No Problems 4 (40) 3 (38) 7 (39) 3 (33) 3 (43) 6 (38) 6 (75) 5 (63) 11 (69) 
Slight Problems 4 (40) 3 (38) 7 (39) 5 (56) 4 (57) 9 (56) 1 (13) 2 (25) 3 (19) 
Moderate Problems 2 (20) 2 (25) 4 (22) 1 (11) 
 
1 (6) 1 (13) 1 (13%) 2 (13) 
Severe Problems   
  
  
     Extreme Problems   
  
  
     
Anxiety 
No Problems 8 (80) 5 (63) 13 (72) 7 (78) 6 (86) 13 (81) 6 (75) 6 (75) 12 (75) 
Slight Problems 2 (20) 2 (25) 4 (22) 1 (11) 1 (14) 2 (13) 1 (13) 2 (25) 3 (19) 
Moderate Problems   1 (13) 1 (6) 1 (11) 
 
1 (6) 1 (13) 
 
1 (6) 
Severe Problems   
  
  
     Extreme Problems                   
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Figure 11: Patients reporting problems by treatment for each of the EQ-5D-5L dimensions.
  
3.4.4 Quality of life measured using the FACT-N subscales and total scores. 
FACT-N is a cancer assessment of patient well-being which is specific to neutropenia. Patients 
answered a series of questions grouped by well-being, which are then collated to give a score 
pertaining to that part of their well-being. The five sections are physical well-being, 
social/family well-being, emotional well-being, functional well-being and a neutropenia 
specific section of questions. The higher the FACT subsection score, the better the patient 
quality of life. Figure 12 compiles the raw scores indicated by each patient at 72 h for the five 
sections, by treatment allocation. Physical, social/family and functional well-being subscales 
score range is 0-28. The emotional well-being range is 0-24 and the neutropenia specific 
subscale range is 0-76.   
The difference seen in Figure 12 between paracetamol and placebo treated median scores was 
not statistically significant in any of the FACT-N sub-sections, Table 7 – Mann-Whitney U Test. 
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Figure 12: Dot-plot for each of the FACT-N subsections by treatment 
 
Eight patients in each treatment group completed the first four well-being subscales, but 
completion of the neutropenia specific section was reduced (paracetamol = 7, placebo = 6). 
The neutropenia specific subscale is the largest and is also the last section, which may have 
been a deterrent for patients to complete it.  
Aggregate scores can be calculated by combining some of the subscale scores to provide 
further quality of life date for interpretation.5 The Trial Outcome Index (TOI) is calculated by 
combining the physical and functional well-being scores with the neutropenia specific score. 
The TOI score ranges from 0 to 132 and includes the variables which are most likely to change 
and are clinically important.5 The median TOI score was 12 higher in the paracetamol treated 
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group than the placebo group, difference not significant. The difference in median the FACT-G 
total score and the median FACT-N total score was also not significant between the treatment 
groups. Total score calculation carried out according to FACT-N scoring guidelines. 
Table 7: FACT-N Subscale and total scores for the study population by treatment  
  Treatment 
p 
  Paracetamol Placebo 
Physical Well-Being (PWB) score range 0-28 
   
n 8 8 
1.00 
median score 15 14 
Social/Family Well-Being (SWB) score range 0-28 
   
n 8 8 
0.65 
median score 27 26 
Emotional Well-Being (EWB) score range 0-24 
   
n 8 8 
0.13 
median score 20 22 
Functional Well-Being (FWB) score range 0-28 
   
n 8 8 
0.80 
median score 15 14 
Neutropenia Specific Well-Being (NS) score range 0-76 
  
n 7 6 
0.37 
median score 55 45 
FACT-N Trial Outcome (TOI) score range 0-132       
Calculated: PWB + FWB + NS = FACT-N TOI 
   n 7 6 
0.14 
median score 80 68 
FACT-G Total Score (score range 0-108) 
   
Calculated: PWB + SWB + EWB + FWB = FACT-G 
   
n 8 8 
0.96 
median score 72 74 
FACT-N Total Score (score range 0-184) 
   
Calculated: PWB + SWB + EWB + FWB + NS = FACT-N Total Score 
  
n 7 6 
0.37 
median score 122 109 
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Chapter 4 – Discussion 
The aim of this study was to use data from a clinical trial of paracetamol during FN to address 
these three specific hypotheses: 
 That paracetamol decreases temperature during febrile neutropenia 
 That paracetamol delays resolution of serum markers of inflammation during febrile 
neutropenia 
 That paracetamol improves quality of life measures during febrile neutropenia 
4.1 Study enrolment 
Although 53 potential participants were assessed for study entry, only 22 were both enrolled 
and started study treatment. One of the reasons for this was that patients who were suitable 
candidates decided not to participate. This may be because patients are already receiving 
unfamiliar treatment and the extra information associated with this trial may have been 
overwhelming. A study carried out by Daughterty et al. investigated the reasons patients 
decide to participate or not participate in phase I therapeutic trials. They found the possibility 
of a therapeutic benefit was the main reason patients participated (85%) but that only a third 
of patients understood all of the information pertaining to the trial.61 Thus the information 
presented at the time of consent may be a deterrent if patients are already overwhelmed with 
new information. In another survey 63% of patients did not want to participate in a trial due to 
randomisation design.62 This may have been a contributing factor to patients in this study 
declining to participate, as they wanted to be sure they received paracetamol due to their 
previous experience of its temperature lowering abilities. 
Another reason for the drop from 53 potential study participants to 22 was the temporal 
separation between patient randomisation and starting study treatment. Patients were 
randomised at the time of their consent for practical reasons. That is, to ensure that when the 
study participants presented with FN they were able to receive treatment as soon as possible, 
rather than waiting for randomisation. This feature of the study design led to a slight mismatch 
in the number of patients who received treatment within each of the two groups, as not all 
patients developed an episode of FN (or were no longer eligible to receive study treatment by 
the time of their FN). Patients who received at least one dose of paracetamol or matched 
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placebo treatment were analysed with an intention to treat analysis according to their 
randomisation status.63 
4.2 Baseline characteristics 
Despite not all randomised patients starting study treatment, of those who received any study 
treatment, baseline characteristics of the two treatment groups were comparable. The 
paracetamol and placebo groups did not differ significantly, with respect to their 
demographics, underlying malignancy and treatment or vital signs at time of FN presentation. 
The maximum age in both treatment groups was 70 years old. However, the risk of developing 
many haematological malignancies, such as acute myeloid leukaemia increases with age.64 One 
of the criteria for study entry was that patients were receiving chemotherapy carrying a high 
risk of FN. This excluded older patients because high-dose chemotherapies are less likely to be 
given to elderly patients given their limited tolerated dose.65  Thus the results of this study 
cannot necessarily be extrapolated to elderly patients, who may be more prone to the adverse 
effects of fever or of paracetamol treatment. 
Median temperature at time of FN presentation in this study was 38.2°C for the whole study 
population. This is similar to the mean initial temperature seen in an Australasian ICU registry 
study including 2,472 patients with neutropenic sepsis and underlying haematological 
malignancies (38.3°C).66 The mean maximum temperature among critically ill ICU patients with 
an infection was determined to be 37.7°C by investigating admission data from New Zealand 
and Australian ICUs.16 This lower temperature indicates that patients with chemotherapy 
induced FN or underlying haematological malignancy can have a higher temperature that 
patients without. 
The MASCC risk index score indicated 27% of patients were at a high risk of neutropenic 
complications. In the validation dataset used during the development of the MASCC score, the 
percentage of MASCC high risk patients was 36%.67 Given that all patients in the current study 
had a haematologic malignancy, a higher percentage of high risk scores might have been 
expected. However, one of the exclusion criteria of the current study was hypotension. Since 
hypotension is one of the grading criteria for the derivation of the MASCC score, this may have 
resulted in fewer high-risk patients being included in this study. It is also possible that the 
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patients who consented to participate in this study developed a better understanding of the 
risks and symptoms of FN due to extra information and education being given for what to look 
for. This may have meant that the patients involved in this study may have been particularly 
motivated, more able to readily recognise their deterioration and more likely to present to the 
hospital faster. Consequently, early recognition and management of their FN may mean that 
they did not become ‘high-risk’ FN patients according to the MASCC score.  
4.2.1 Clinical outcomes 
The percentage of patients who reached the ‘successful treatment’ criterion in this study 
(according to protocol criteria) was lower than anticipated (27% versus 50% predicted). This 
could have a significant impact on power calculations for a full study using ‘successful 
treatment’ as a primary outcome measure. 
A study of oral versus intravenous antibiotic therapy in FN patients from 1999 included 
patients more than once if they presented with recurring episodes of FN.68 The 1999 study 
resulted in successful treatment for 69% of episodes and the criteria for treatment failure 
included: antibacterial regimen modification or escalation, intolerance to treatment, or 
death.68 Although this study elucidated a higher success rate the inclusion of the same patient 
for multiple episodes may have biased their study. The study population did not include 
patients which were a high risk of developing infectious complications or FN.68 However all of 
the patients in the current study were at a high risk of developing FN and so this could be the 
major factor contributing to our lower successful treatment rate. Also the patients involved in 
our study of paracetamol in FN were adults, whereas this study included children (at least  5 
years old).68 It should be noted that the high rate of successful treatment found in other 
studies may be due to the inclusion of only low-risk patients.69 The inclusion criteria for the 
current study meant that only high-risk patients are included, which may have had a dramatic 
impact on treatment success.  Also, perhaps patients with a haematological malignancy are at 
higher risk of treatment failure due to: increased likelihood of indwelling lines, increase fungal 
infections, increased chance of changing antibiotics due to close medical monitoring (when 
perhaps not always necessary). However, it must be remembered that according to MASCC 
score grading less than a third of patients involved in the current stud y were graded with a 
high risk of developing FN complications. 
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The length of hospital admission was not significantly different between the two treatment 
groups. However, this measure may be a poor measure of infection resolution. For example, it 
was obvious that the duration of stay was extended by further inpatient chemotherapy 
treatment in some patients (as long as 52 days in one patient). An American study in 2005 of 
6,799 children with FN found the median length of hospital stay to be 5 days.70 Further analysis 
found this value was influenced significantly by a variety of factors to increase the length of 
hospital admission in patients; ethnicity, age, complications such as infection and type of 
malignancy.70 The median length of admission for patients in the current study was 11.5 days, 
this longer admission time may due to chance, as we were analysing a much smaller 
population group (n = 22). However, in this group of high-risk patients, some may have just 
come in to start their treatment when they presented with FN, whereas others may have 
almost finished chemotherapy. Thus, the mean length of hospital admission may not 
accurately reflect the duration of the infection. 
The dose of paracetamol administered to the patients (one gram every six hours) was within 
recommended dosing guidelines.71 One placebo-treated patient presented with grade one 
hyperbilirubinaemia.  A single paracetamol-treated patient presented with grade one 
transaminitis before starting paracetamol. This resolved by 24 hours on paracetamol, but had 
returned by 72 hours. The timing of this mild transaminitis and hyperbilirubinaemia does not 
suggest a relationship to paracetamol, which concurs with the attitude of Clark et al. when 
discussing liver toxicity in terms of paracetamol suicide.72 Other causes for this transaminitis 
could include antibiotics, the neutropenic infection itself or prior chemotherapy. Overall, 
despite limited numbers, there was no evidence of liver dysfunction inducted by paracetamol 
within this study. Notably, a randomised trial investigating the ability of paracetamol to reduce 
temperature after stroke gave a higher dose of 6g paracetamol daily to 697 patients, and did 
not find significant toxicity.73 
 




4.3.1 The effect of paracetamol on temperature 
This study found a significant difference in both daily peak and daily mean temperature 
between treatment groups, indicating that paracetamol is an effective antipyretic in FN. 
Inclusion of both measures is important: patients were more likely to have their temperature 
measured if they complained of fever, therefore symptomatic patients (e.g. on placebo) may 
have higher peak temps just because their temperature was measured more often. Conversely 
asymptomatic patients may miss measurements, even if febrile, so fevers are missed. 
Therefore it is relevant that many individual time-points were also significantly different 
between treatment groups. 
The magnitude of the temperature difference we found was greater than the anti-pyretic 
effect reported in the recently-published HEAT randomised controlled trial (mean peak 
temperature difference: 0.25°C, mean average temperature difference: 0.28°C).74 The HEAT 
trial investigated the effectiveness of paracetamol for reducing temperature in patients 
presenting to the ICU with sepsis. The HEAT trial differs from the current study as they 
administered paracetamol (1 g every 6 hours) intravenously.74 This was done to avoid any 
differences the patients might have in their ability to absorb paracetamol.74 Due to potentially 
varying efficacy and pharmacokinetics of oral and intravenous treatment routes this 
administration could have contributed to the smaller antipyretic effect they found. The peak 
temperature in the HEAT study in the 12 hours preceding randomization was 38.8°C in the 
paracetamol group and 38.7°C in the placebo treated group.74 These temperatures are higher 
than the median presenting temperature for each group in the current study (paracetamol 
38.1°C, and placebo 38.3°C). But the fevers presenting in the patients of the HEAT study are 
likely due to many different causes, and only 20% of patient had any form of cancer.74 These 
different causes of infection and patient characteristics may have resulted in a different 
aetiology of fever and therefore greater presenting temperatures. By contrast, an ICU registry 
study by Weinkove et al. found the mean peak temperature in cases of neutropenic sepsis to 
be 38.1°C and 37.5°C for non-neutropenic cases suggesting that the temperatures of patients 
with FN would be higher.66 
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The HEAT study was set in the context of the ICU; where additional physiological interventions 
are routinely used that may have lowered temperatures in the placebo treated group (e.g. 
dialysis, ventilation), potentially diminishing the impact of paracetamol use. Limited physical 
cooling measures were allowed in the current study; however their effect may have been a co-
contaminant treatment on the observed effectiveness of paracetamol. 75 
In conclusion, our results prove the first hypothesis, that paracetamol decreases temperature 
during febrile neutropenia. 
4.3.2 The effect of paracetamol on serum biomarkers 
Paracetamol effectively reduced temperature in patients presenting with FN. Fever is marker 
of infection – if fever is effectively reduced then it can no longer be used as an indicator of the 
degree of resolution of the infection. Thus biomarkers could be useful substitute markers for 
measuring infection persistence in a clinical trial of paracetamol use. Further utility of 
biomarkers includes stratifying patients early in their FN course into groups who are at a high 
risk of developing adverse outcomes, and who might be candidates for early escalation of 
treatment. 
All of the investigated biomarkers were raised from the reference ranges for healthy patients 
found through literature review. This indicates that these biomarkers are raised during 
infection.  
IL-6 levels were found to also be significantly increased in a study involving adult 
chemotherapy induced FN patients and in another investigating FN in children.76 The results of 
the current study when considered with this previous literature confirm that IL-6 is elevated at 
presentation. Further, the normalisation of IL-6 levels seen in the current study from 4 h (peak 
concentration) to 72 h was also found in a study carried out by Vanska et al; where IL-6 levels 
were raised at presentation and then declined by the second day of FN.57 This dynamic action 
of IL-6 during FN could lead to its use as a biomarker of FN resolution. Aggarwal et al. also 
found that IL-6 levels were raised (> 100 pg/mL) in patients who were at a high risk of 
developing adverse outcomes.47 This correlation with adverse outcomes was confirmed in the 
current study at presentation with FN and 4 h after presentation. Thus, early IL-6 levels could 
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be used in future studies to identify patients who are at risk and monitor their FN closely or 
escalate their treatment. 
Literature has pointed to IL-8 levels being elevated during cases of FN 77,78 this was also seen in 
the current study where study participants recorded concentrations over 100 times higher 
than the 20 pg/mL reference range.53 IL-8 levels were raised at presentation and clearly 
peaked at 4 hours which correlated with being associated with adverse outcomes. Schuler  et 
al. found that patients with significantly higher IL-8 went on to develop complications later in 
their FN which is consistent with the results of the current study.79 
IL-10 showed the same kinetics as found in previous studies of FN, where it was raised at 
presentation, peaked clearly at 4 hour and declined thereafter.33,48 However the changes in 
concentration in the first 72 h of FN were not of a magnitude for future utility to be able 
stratify patients by their potential to develop adverse outcomes. 
C-reactive protein and procalcitonin both have limited results and thus the analysis of their 
utility is also limited. Due to only obtaining presentation and 72 h CRP samples it is difficult to 
analyse their dynamics. From the analysis of available samples it is shown to have higher 
concentrations at the later time point. However, the peak concentration may have occurred 
between these times as found in a study by Vanska et al. where the peak CRP concentration 
was found between day two and three.33 No correlations were found in the current study 
between CRP concentration and the development of adverse outcomes, again these 
correlations may have been missed due to the omitted samples, as it has previously been 
shown that CRP concentration is an independent risk factor for poor clinical outcomes.8 
Procalcitonin has been reported to peak within the first 24 h of FN,6 but due to data obtained 
in the current study being below the LOD for the PCT ELISA it is difficult to determine whether 
the peak seen in the 24 h sample is reliable. Elevated PCT levels have previously been 
associated with mortality and ICU admission.31,44 The data from the current study is 
inconsistent with these findings as correlation with adverse outcomes was found at 
presentation and 4 h, whereas elevated PCT was seen at 24 and 72 h, but it is likely that the 
management of samples below the LOD may have caused this significance.  Due to the 
difference in testing ‘latitude’ for PCT, future investigations would need to use an analysis with 
increase dynamic range at the lower end of the PCT concentration range. 
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The biomarker PCT and CRP have been shown in this study to peak later in FN than IL-6 or IL-8. 
Therefore their levels may not be as useful in a clinical setting as they peak at a stage where it 
is too late to intervene to prevent some adverse outcomes. Whereas biomarkers which 
provide information at presentation or in the early stages of FN give actionable information 
may then be used to mitigate potential risks. Methods which could be implemented to avoid 
adverse outcomes include antibody therapy escalation, and close patient monitoring. IL-6 and 
IL-8 have been shown in this study to be potential early biomarkers of FN. 
There is limited literature pertaining to the value of TNF-α as a biomarker in cases of FN. A 
study in 1999 and one in 2001 both found that the baseline levels of TNF-α between patients 
with FN and without FN were similar.78,80 This is consistent with the little change observed in 
TNF-α levels among all patients in the current study. 
The pathways which serum biomarkers act may be independent of temperature homeostasis 
pathways that are affected by paracetamol. Therefore although paracetamol affected 
temperature it had no effect on biomarkers as found in a study of healthy patient treated for 
fevers after an endotoxin challenge, measuring TNF-α, IL-6 and IL-8.27 This lack of effect was 
also seen in the current study. 
In conclusion, paracetamol did not delay the resolution of serum markers of inflammation 
during febrile neutropenia. It is feasible to measure biomarker levels in cryopreserved serum 
samples. Both IL-6 and IL-8 were shown to be dynamic and indicative of adverse outcomes in 
the early stages of FN and so may be useful as potential biomarkers. 
4.3.3 The effect of paracetamol on quality of life 
Even if paracetamol treatment has no impact on the clinical outcomes of infection, it would be 
reasonable to use paracetamol if it leads to improved QoL by alleviating the symptoms of 
fever. The HEAT trial found paracetamol to have no definite impact on clinical outcomes; 
however it did not measure associated QoL. In the current study paracetamol was found to 
effectively reduced temperature during FN. This antipyretic effect was unexpectedly coupled 
with a decrease in patient QoL. Potential reasons for this unanticipated reduction of QoL are 
outlined below.  
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The first reason may be that both IV and oral paracetamol have been shown to decrease blood 
pressure – due to acting on prostaglandins.81 Such adverse haemodynamic effects may make 
patients feel unwell and therefore adversely affect quality of life.  
Second, all patients with high fevers during this study were allowed other physical cooling 
measures. Paracetamol was found to effectively reduce temperature in this population, and so 
placebo-treated patients may have complained more of temperature and given cooling cares 
to reduce their discomfort. Thus the placebo cohort may have received more nursing 
attention, which may have positively influenced their perception of nursing or medical care 
and led to greater interaction with staff, improving their self-reported quality of life.  
Third, paracetamol has been recently shown to dull both pain and pleasure. So when the 
paracetamol-treated patients are reporting their QoL they may not feel any worse but nor do 
they feel any better. This may mean that as patients feel no better they report a worse QoL as 
they are expecting an improvement.82 Previous studies have also found paracetamol treatment 
to result in more patients complaining of chills and perception of fever than in patients treated 
with placebo or aspirin.27 
Finally, it must be remembered that this is a small study (n = 22), which was not powered to 
detect differences in quality of life. Due to the small sample size type one and type two errors 
may have occurred in analysis. It is also important to be cautious with conclusions especially as 
there were several missing QoL questionnaires or sections. The missing data may have been 
the most extreme or interesting data. Were these questionnaires omitted by chance? Did 
these patients feel too poorly to complete the questionnaires (informative dropout – where if 
patient condition worsens then they may be more likely to leave)? Did they feel so well that 
they were off the ward and missed the opportunity to complete the questionnaires? This is a 
well-recognised issue with QoL measurement, and is not easily addressed, especially in a study 
of this size.83 Future studies should make use of dedicated trial nurses to help ensure QoL 
measures are completed. 
In the current study two different QoL questionnaires which were used were both made up of 
subsections of questions. Thus these self-reported questionnaires led to many end-points for 
analysis, however, this multitude of variables for analysis could contribute to type one and two 
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errors in analysis.84 To overcome this in a full study it may be of use to simplify and reduce the 
QoL questionnaires.  
To take a baseline QoL measure for each patient at the time of their consent would make the 
measure more robust.55 This is because QoL is so variable due to patient perception, condition 
and inpatient status.85 A baseline QoL value could be used to normalise patients and enable 
analysis of percentage increases/decreases in QoL. 
To summarise, this study did not find that paracetamol improved patient quality of life during 
FN, and in fact suggested that QoL may be reduced as a result of paracetamol treatment.  To 















Samples were plated in duplicate for biomarker analysis on the Bio-Plex Pro™ Human Cytokine 
8-plex Assay and the Procalcitonin Human ELISA Kit. Triplicate sample plating would have been 
desirable to confirm results. However due to the 96-well plate configuration of both of these 
kits there were enough wells for each sample to be plated twice only. Reassuringly however, 
all duplicates resulted in very similar concentrations and so the average of the two readings 
was used for analysis. 
For the purposes of all the analyses of biomarkers, missing values were ignored, and the 
available values only were used. It is not clear whether the missing values across all aspects of 
the study are due to omission of collection or worsening FN. In some cases, values will be 
missing due to chance (a sample happens to have been forgotten). However, in other cases, 
blood was not taken due to a patient's clinical deterioration leading to their removal from the 
study, or leading medical or nursing staff to forget the study sample. The omission of such 
results can lead to bias of the remaining available results. The attrition of samples will rise over 
time through a study such as this as patient condition worsens. Therefore it is better to focus 
on serum biomarkers at earlier time-points in FN to ensure comparable sample numbers 
among treatment groups. It is possible that to focus sample collection to be more often during 
the first 24 h of FN will provide the most robust results, due to minimisation of sample 
omission. Another option would be to allow samples to be collected even after patient 
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4.5 Future study directions 
The data generated from this randomised control trial and subsequent study analysis have 
given good insights into potential future directions.  
Taking into account both recruitment rates and successful treatment rates, revised power 
calculations can be undertaken:  
To detect a difference of 10% in successful treatment rates between two groups (25% and 
35%) at 80% power and with alpha of 5% (two-sided), a sample size of 329 per group would be 
necessary, which implies screening 1586 patients and recruiting 1107 patients to a randomised 
trial.86 In practice, a trial of this size would be difficult to conduct in a country the size of NZ, 
even in a multicentre setting. Alternative options could include powering the trial based on 
QoL measures or duration of hospital stay.  
For a future study to confirm the utility of serum biomarkers as markers of infection during FN 
the primary and secondary end points would need to be clinically meaningful. Such end points 
could be those used in the phase II feasibility study such as survival and duration of antibiotic 
therapy.  
The stipulation in the study protocol that patients be randomised at the time of consent meant 
that the blinding of both patients and staff was maintained. This meant that there were a 
number of patients who were randomised that did not go on to receive treatment. When 
considering the patients recruited who did not begin treatment, it should still be 
recommended that patients are still randomised in the same manner for future related 
interventional studies to maintain blinding. 
At this time of randomisation it would be advantageous to take baseline measures to use as 
internal reference ranges, which would be more tailored to the study than reference ranges 
obtained from the literature. These measures could be used to index patients to reduce the 
effect of individual variation on subsequent analysis. Baseline measures should include blood 
samples for analysis of serum biomarkers, vital signs and quality of life questionnaires. 
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Individual variation cannot be ignored as a major contributing factor for the range of 
temperatures recorded, serum biomarkers concentrations and self-reported quality of life 
measures. Thus carrying out a larger trial would be beneficial to enable a stronger population 
norm for all of the aforementioned measures. The patients whose condition worsens, which 
requires them to be admitted to the ICU or HDU would remain in the study to record their 
temperatures and biomarker concentrations. 
It would be of interest to investigate whether the utility of serum biomarkers in FN is 
influenced by the type of malignancy or aetiology of the infection. Whether the pathology of 
the kind of cancer impacts on the production of biomarkers of infection could provide further 














The results and subsequent analysis this study generated has led to the following conclusions: 
1. That IL-6 and IL-8 are the most promising biomarkers further investigation during FN. 
IL-6 and IL-8 both showed elevated concentrations from reference ranges at 
presentation, and increased further at 4 h. The early elevation of these two 
biomarkers was associated with development of adverse outcomes. Although we are 
unable to conclude whether or not they are affected by treatment allocation in this 
trial. 
2. That paracetamol does not lead to significant improvement in patient QoL during FN. 
Results have suggested that paracetamol may in fact reduce QoL, this needs 
confirmation in a further trial. 
3. That paracetamol does effectively reduce temperature in FN patients.   For clinicians, 
these results imply that paracetamol can be relied upon as an effective and safe 
antipyretic in FN for symptomatic fevers. However, regular use to suppress fevers was 
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Appendix i. Table used to determine hyperbilirubinaemia, transaminitis and alkaline phosphatase 
grades for liver toxicity. Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4.03, 2010. U.S. Department of Health and Human Services, National Institutes 
of Health National Cancer Institute, U.S.A. Pg 107. 
 
 
 
 
